FDA Panel votes 11-0 benefits outweigh risks of Onyx's (ONXX) carfilzomib
Tweet
Share
E-mailGet Alerts ONXX Hot Sheet
Join SI Premium – FREE
An FDA Panel has just voted 11-0 benefits outweigh risks of Onyx's (Nasdaq: ONXX) carfilzomib
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
- FDA clears Implantica's RefluxStop implant for U.S. market
- AC Immune reports early Phase 1 data for NLRP3 inhibitor ACI-19764
Create E-mail Alert Related Categories
FDA, Hot FDA News, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
